Related coverage linked through entity extraction aliases.
Mar 16, 2026
Analysts updated ratings on healthcare stocks: Ultragenyx remains Strong Buy, Immutep downgraded to Hold, BridgeBio gets Buy. American Well and Baxter stay Hold. Upside ranges from 11% to 154%.
Jul 25, 2026
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
Mar 03, 2026
The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.
Feb 24, 2026
Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.
